Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders
Claudia J. Diehl, Alessio Ciulli
Chemical Society Reviews (2022) Vol. 51, Iss. 19, pp. 8216-8257
Open Access | Times Cited: 120

Showing 1-25 of 120 citing articles:

Proximity-Based Modalities for Biology and Medicine
Xingui Liu, Alessio Ciulli
ACS Central Science (2023) Vol. 9, Iss. 7, pp. 1269-1284
Open Access | Times Cited: 83
Expanding PROTACtable genome universe of E3 ligases
Yuan Liu, Jingwen Yang, Tianlu Wang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 71
Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design
Johannes Krieger, F.J. Sorrell, Ansgar Wegener, et al.
ChemMedChem (2023) Vol. 18, Iss. 8
Closed Access | Times Cited: 37
Small-Molecule Ferritin Degrader as a Pyroptosis Inducer
Yu Chen, Wen Li, S. Chul Kwon, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 17, pp. 9815-9824
Closed Access | Times Cited: 32
A beginner’s guide to current synthetic linker strategies towards VHL-recruiting PROTACs
Nikol A. Zografou-Barredo, Alex J. Hallatt, J. S. JUN. RICCI, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 88-89, pp. 117334-117334
Open Access | Times Cited: 31
Discovery of SMD-3040 as a Potent and Selective SMARCA2 PROTAC Degrader with Strong in vivo Antitumor Activity
Lin Yang, Wenbin Tu, Liyue Huang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 15, pp. 10761-10781
Closed Access | Times Cited: 31
Clinical Translation of Targeted Protein Degraders
Nikki R. Kong, Lyn H. Jones
Clinical Pharmacology & Therapeutics (2023) Vol. 114, Iss. 3, pp. 558-568
Closed Access | Times Cited: 29
Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design
Dazhao Mi, Yuzhan Li, Haijun Gu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 256, pp. 115444-115444
Closed Access | Times Cited: 27
The rise of degrader drugs
Mingxing Teng, Nathanael S. Gray
Cell chemical biology (2023) Vol. 30, Iss. 8, pp. 864-878
Open Access | Times Cited: 27
E3 Ligases Meet Their Match: Fragment-Based Approaches to Discover New E3 Ligands and to Unravel E3 Biology
Iacovos N. Michaelides, Gavin W. Collie
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 5, pp. 3173-3194
Open Access | Times Cited: 26
Design, synthesis and biological evaluation of KRASG12C-PROTACs
Xiaoyi Zhang, Tong Zhao, Minghao Sun, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 78, pp. 117153-117153
Closed Access | Times Cited: 25
PROTACs: A novel strategy for cancer drug discovery and development
Xin Han, Yi Sun
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 24
A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death
Jonathan Mannion, Valentina Gifford, Benjamin R. Bellenie, et al.
Immunity (2024) Vol. 57, Iss. 7, pp. 1514-1532.e15
Open Access | Times Cited: 14
Structure-Guided Design and Optimization of Covalent VHL-Targeted Sulfonyl Fluoride PROTACs
Rishi R. Shah, Elena De Vita, Preethi S. Sathyamurthi, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 6, pp. 4641-4654
Open Access | Times Cited: 12
A small molecule VHL molecular glue degrader for cysteine dioxygenase 1
Antonin Tutter, Dennis L. Buckley, Andrei A. Golosov, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 10
The cyclimids: Degron-inspired cereblon binders for targeted protein degradation
Saki Ichikawa, N. Connor Payne, Wenqing Xu, et al.
Cell chemical biology (2024) Vol. 31, Iss. 6, pp. 1162-1175.e10
Open Access | Times Cited: 10
An engineered DNA aptamer-based PROTAC for precise therapy of p53-R175H hotspot mutant-driven cancer
Lingping Kong, Fanlu Meng, Ping Zhou, et al.
Science Bulletin (2024) Vol. 69, Iss. 13, pp. 2122-2135
Open Access | Times Cited: 10
Expanding the ligand spaces for E3 ligases for the design of protein degraders
Rahman Shah Zaib Saleem, Martin P. Schwalm, Stefan Knapp
Bioorganic & Medicinal Chemistry (2024) Vol. 105, pp. 117718-117718
Open Access | Times Cited: 8
Discovery of SMD-3236: A Potent, Highly Selective and Efficacious SMARCA2 Degrader for the Treatment of SMARC4-Deficient Human Cancers
Lin Yang, Wenbin Tu, Lingying Leng, et al.
Journal of Medicinal Chemistry (2025)
Closed Access | Times Cited: 1
Identification of novel 7-hydroxycoumarin derivatives as ELOC binders with potential to modulate CRL2 complex formation
Y. Kim, Seung Jae Baek, Eun-Kyung Yoon, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Revolutionizing Drug Targeting Strategies: Integrating Artificial Intelligence and Structure-Based Methods in PROTAC Development
Mohd Danishuddin, Mohammad Sarwar Jamal, Kyoung Seob Song, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 12, pp. 1649-1649
Open Access | Times Cited: 17
Mechanism of degrader-targeted protein ubiquitinability
Charlotte Crowe, Mark A. Nakasone, Sarah Chandler, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 7
The value of protein allostery in rational anticancer drug design: an update
Ruth Nussinov, Hyunbum Jang
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 9, pp. 1071-1085
Open Access | Times Cited: 7
Selective degradation of BRD4 suppresses lung cancer cell proliferation using GSH-responsive PROTAC precursors
Heli Fan, Zhili Zhou, Dehao Yu, et al.
Bioorganic Chemistry (2023) Vol. 140, pp. 106793-106793
Closed Access | Times Cited: 14
Antibody-Proteolysis Targeting Chimera Conjugate Enables Selective Degradation of Receptor-Interacting Serine/Threonine-Protein Kinase 2 in HER2+ Cell Lines
Karina Chan, Preethi S. Sathyamurthi, Markus A. Queisser, et al.
Bioconjugate Chemistry (2023) Vol. 34, Iss. 11, pp. 2049-2054
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top